Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-208969
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $343,970 | $205,749 |
| General and administrative | 101,252 | 35,011 |
| Total operating expenses | 445,222 | 240,760 |
| Loss from operations | (445,222) | (240,760) |
| Non-operating income (expense), net: | ||
| Interest income | 19,508 | 24,915 |
| Interest expense | (12,197) | — |
Item 1. Financial Statements.
FAQ
- What is Revolution Medicines, Inc.'s R&D?
- Revolution Medicines, Inc. (RVMD) reported R&D of $343.97M in Q1 2026.
- How has Revolution Medicines, Inc.'s R&D changed year-over-year?
- Revolution Medicines, Inc.'s R&D increased by 67.2% year-over-year, from $205.75M to $343.97M.
- What is the long-term trend for Revolution Medicines, Inc.'s R&D?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s R&D has grown at a 51.6% compound annual growth rate (CAGR), from $186.95M to $987.33M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Revolution Medicines, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude